Hypereosinophilic syndrome presenting as coagulopathy

Table 3 Evaluation of genetically based myeloproliferative disorders, malignancies, and primary immune deficiencies

JAK2 V617F mutation	Not detected
CALR mutation	Not detected
JAK2 Exon 12 mutation	Not detected
MPL Exon 10 mutation	Not detected
CSF3R Exon 14/17 mutation	Not detected
Hereditary hemochromatosis DNA mutation analysis	No mutations detected
SCFD2, LNX, FIP1L1, CHIC2, PDGFRA/KIT on Chromosome 4q12	No rearrangements detected on interphase fluorescence in situ hybridization (IFISH)
PDGFRB	No rearrangements detected on IFISH
FGFR1	No rearrangements detected on IFISH
BCR/ABL p210 Interpretation	No BCR/ABL b2:a2 (e13:a2) or b3:a2 (e14:a2) transcripts detected
University of Washington Heme Gene Panel (ASXL1, CBL, CSF3R, DNMT3A, EZH2, FBXW7, FGFR1, FLT3, GATA1, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KMT2A, KRAS, MAP2K1, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, RB1, RUNX1, SF3B1, SRSF2, STAG2, STAT3, TET2, TP53, U2AF1, WT1, ZRSR2)	No pathogenic mutations detected

ISSN: 1710-1492